BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FT836 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of FT836\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07216105-2486@assetmemo.bio
DTSTAMP:20261121T005330Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:FT836: Phase 1 readout est. (NCT07216105)
DESCRIPTION:FT836\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: FT836 Wit
 h or Without Chemotherapy and/or Monoclonal Antibodies\, in Participants W
 ith Advanced Solid Tumors\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ft836#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07216105
URL:https://assetmemo.bio/drug/ft836#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221032-2486@assetmemo.bio
DTSTAMP:20261121T005330Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:FT836: Phase 1 readout est. (NCT07221032)
DESCRIPTION:FT836\, phase 1.\nStudy: FT836 CAR T-cell Therapy in Combinatio
 n With Daratumumab in Patients With Relapsed and/or Refractory Multiple My
 eloma\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ft836#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07221032
URL:https://assetmemo.bio/drug/ft836#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
